Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission’s (EC) approval of Praluent (alirocumab) for a new indication. The approval enables Praluent to be used as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) levels in adults with atherosclerotic cardiovascular disease (ASCVD), aiming to lower the risk of further cardiovascular […]
In a significant milestone for Belgian biopharma company Ablynx, the U.S. Food and Drug Administration (FDA) has granted approval for Cablivi (caplacizumab-yhdp), a nanobody designed to treat acquired thrombotic thrombocytopenic purpura (aTTP). The FDA’s decision enables the drug to be used in combination with plasma exchange and immunosuppressive therapy, providing a much-needed treatment option for […]
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving it as an add-on maintenance therapy for two specific types of asthma. This latest approval marks a pivotal advancement for patients with moderate-to-severe asthma. New FDA Approval for Dupixent: Key Details The FDA’s green light […]
Significant Investment in Vaccine Production: French pharmaceutical giant Sanofi has announced plans to invest CAD 500 million (approximately $396.3 million) to construct a new vaccine manufacturing facility at its Canadian headquarters, Sanofi Pasteur, in Toronto. This development is aimed at bolstering the company’s operational capabilities in Canada and reaffirming its commitment to advancing global public […]
French pharmaceutical giant Sanofi has successfully finalized an agreement to acquire Ablynx, a Belgian biotechnology firm, for approximately €3.9 billion. This strategic acquisition surpasses a previous offer of €2.6 billion from Danish pharmaceutical company Novo Nordisk, which Ablynx had rejected citing undervaluation. Details of the Acquisition Ablynx, based in Ghent and established in 2001 as […]
Sanofi has announced a definitive agreement to acquire Bioverativ, a US biotechnology company specializing in the treatment of hemophilia and other rare blood disorders, for approximately $11.6 billion. The all-cash transaction will involve Sanofi purchasing all outstanding shares of Bioverativ at $105 per share, marking a significant expansion of Sanofi’s presence in specialty care and […]
Sanofi and Principia Biopharma have announced a significant partnership to develop and commercialize PRN2246, a promising oral drug candidate for multiple sclerosis (MS) and other central nervous system (CNS) diseases. The deal, which could be worth up to $805 million, positions PRN2246, a Bruton’s tyrosine kinase (BTK) inhibitor, at the forefront of MS treatment development. […]
Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. This marks Dupixent as the first biologic medication approved for patients who have not responded adequately to traditional topical prescription treatments […]
AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals.
AstraZeneca’s biotech arm, MedImmune, and Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, have entered into a significant research and development collaboration. The partnership, valued at approximately €615 million, aims to advance the development of MEDI8897, a monoclonal antibody for treating respiratory syncytial virus (RSV) infections in infants and children. Strategic Collaboration to […]
The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has succeeded in a pivotal phase 3 Atopic dermatitis clinical trial.
Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase 3 clinical trial for adults with uncontrolled moderate-to-severe atopic dermatitis (AD). Breakthrough in Atopic Dermatitis Treatment The CHRONOS trial, a critical phase 3 study, involved Dupixent administered alongside topical corticosteroids […]
